- Other Post Graduate Training - Stanford University (2006-2010)
- Fellowship - Johns Hopkins Hospitals & Health System (2002-2006), Medical Oncology
- Medical School - University of Rochester School of Medicine and Dentistry (1990-1999)
- Medical School - University of Rochester School of Medicine and Dentistry (1992-1997)
- Residency - University of Rochester/Strong Memorial Hospital (2000-2002), Internal Medicine
- Internship - University of Rochester/Strong Memorial Hospital (1999-2000), Internal Medicine
James Kim, M.D., Ph.D.
- Internal Medicine - Hematology/Oncology
- Lung Cancer
Dr. James Kim received his M.D. and Ph.D. degrees from the University of Rochester, where he also completed his Internal Medicine Residency. Dr. Kim completed a medical oncology fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. During his fellowship, Dr. Kim joined the laboratory of Dr. Philip Beachy (at both Johns Hopkins and Stanford University) where he studied the role of Hedgehog signaling pathway, a critical developmental pathway, in cancer and small molecule inhibitors of this pathway.
At UT Southwestern, Dr. Kim’s laboratory focuses on how fundamental developmental pathways, such as Hedgehog, are involved in the initiation, growth, and metastases of cancers through the use of cancer mouse models and cell and molecular biological techniques. The laboratory also seeks to understand interactions of these pathways with each other and between tumor epithelia and stroma. In his clinic, Dr. Kim specializes in the care of patients with lung cancer and other thoracic malignancies.
Education & Training
Professional Associations & Affiliations
- American Society of Clinical Oncology (2002)
- American Association for Cancer Research (2003)
- International Association for the Study of Lung Cancer (2012)
Honors & Awards
- American Society of Clinical Oncology Young Investigator Award 2005
- National Lung Cancer Partnership Young Investigator Research Grant 2010
- Simmons Cancer Center and American Cancer Society New Investigator Award 2012
Books & Publications
Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Mar 32 8 745-51
Posaconazole, a second-generation triazole antifungal drug, inhibits the Hedgehog signaling pathway and progression of basal cell carcinoma.
Chen B, Trang V, Lee A, Williams NS, Wilson AN, Epstein EH, Tang JY, Kim J Molecular cancer therapeutics 2016 Jan
Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder
Shin K, lee J, Guo N, Kim J, Lim A, Qu L, Mysorekar IU, Beachy PA Nature 2011 Apr 7 472 (7341) 110-4
Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response.
Myers BR, Sever N, Chong YC, Kim J, Belani JD, Rychnovsky S, Bazan JF, Beachy PA Developmental cell 2013 Aug 26 4 346-57
Thermodynamics of coaxially stacked helixes with GA and CC mismatches
Kim J, Walter AE, Turner DH Biochemistry 1996 Oct 29 35 (43) 13753-61
Simultaneous measurement of smoothened entry into and exit from the primary cilium.
Kim J, Hsia EY, Kim J, Sever N, Beachy PA, Zheng X PloS one 2014 9 8 e104070
Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma
Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, Edwards MS, Fisher PG, Weissman IL, Rowitch DH, Vogel H, Wong AJ, Beachy PA Proceedings of the National Academy of Sciences 2011 Mar 15 108 (11) 4453-8
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH, Beachy PA, Rudin CM Cancer cell 2013 Jan 23 1 23-34
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA Cancer Cell 2010 Apr 13 17 (4) 388-99
Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector
Kim J, Lee JJ, Kim J, Gardner D, Beachy PA Proceedings of the National Academy of Sciences 2010 Jul 27 107 (30) 13432-7
- Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
- Tumor Epithelial-Stromal Interactions
- Molecularly Targeted Therapy
- Lung Cancer
- Hedgehog Signaling Pathway
- Developmental Pathways
- Lung Cancer